Development and validation of RP-HPLC and RP-UPLC methods for quantification of erythropoietin formulated with human serum albumin  by Rane, Shaligram S. et al.
Contents lists available at ScienceDirect
www.elsevier.com/locate/jpa
Journal of Pharmaceutical Analysis
Journal of Pharmaceutical Analysis 2012;2(2):160–1652095-1779 & 2011 Xi
by Elsevier B.V. All
Peer review under re
doi:10.1016/j.jpha.20
Produc
nCorresponding au
fax: þ91 265 795552/
E-mail address: pwww.sciencedirect.comORIGINAL ARTICLE
Development and validation of RP-HPLC and RP-UPLC
methods for quantiﬁcation of erythropoietin formulated with
human serum albumin
Shaligram S. Ranea,b, Alkesh Ajamerib, Rustom Modyb, P. Padmajac,n
aDepartment of Applied Chemistry, Faculty of Technology and Engineering, The Maharaja Sayajirao University of Baroda,
Vadodara, Gujarat, India
bIntas Biopharmaceuticals Ltd., Ahmedabad, Gujarat, India
cDepartment of Chemistry, Faculty of Science, The Maharaja Sayajirao University of Baroda, Vadodara, Gujarat, India
Received 8 August 2011; accepted 4 November 2011
Available online 29 November 2011KEYWORDS
Recombinant
erythropoietin (EPO);
Human serum albumin
(HSA);
Reverse phase HPLC
(RP-HPLC);
Ultra performance
liquid chromatography
(UPLC);
Validation’an Jiaotong Univ
rights reserved.
sponsibility of Xi’a
11.11.006
tion and hosting by El
thor. Tel.: þ91 937
331130.
_padmaja2001@yaAbstract Rapid and sensitive reverse phase high performance liquid chromatography (RP–HPLC)
and ultra performance liquid chromatography (UPLC) methods with UV detection for quantiﬁca-
tion of erythropoietin (EPO) in presence of human serum albumin (HSA) as a stabilizer in a
pharmaceutical formulation of EPO have been developed and validated. Chromatography was
performed with mobile phase containing 0.1% Triﬂuoroacetic acid (TFA) in MilliQ water and
0.1% TFA in acetonitrile with gradient program and a ﬂow rate of 1.5 mL/min for HPLC and
0.35 mL/min for UPLC. Quantiﬁcation was accomplished with internal reference standard
(qualiﬁed using EP reference standard). The methods were validated for linearity (correlation
coefﬁcient¼0.99), accuracy, precision and robustness. Robustness was conﬁrmed by considering
three factors; percentages of TFA in mobile phase, age of test sample and mobile phase and column
temperature. Intermediate precision was conﬁrmed by different analysts, different equipments and
on different days. The relative standard deviation (RSD) value (o2%, n¼30) indicated good
precision of the developed method. The proposed RP-HPLC method had retention time less than
20 min while the developed UPLC method had retention time less than 4 min. Both the RP-HPLC
and UPLC methods were simple, highly sensitive, precise and accurate, suggesting that the
developed methods are useful for routine quality control.
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1. Introduction
Erythropoietin (EPO) is a glycoprotein produced primarily by
the kidney, which regulates the production of red blood cells
[1]. EPO has been expressed using recombinant DNA technol-
ogy and pharmaceutical preparations of recombinant human
EPO are now available from several manufacturers around the
world [2].
Since recombinant protein molecule readily undergoes
structural changes as a result of oxidation, deamination and
aggregation (dimer and polymer formation), appropriate
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throughout the reported shelf life, is important [3–5].
The development of analytical methods for the direct analysis
of the active drug substance (protein) in these pharmaceutical
preparations may present some difﬁculties as the amount of EPO
present in these formulations is very small compared to the large
amount of HSA added as an excipient to prevent adsorption of
the protein to the vial/storage container walls and to increase
stability during storage [6,7]. Serge Rudaz et al. have summarized
in their review the analytical techniques available for intact
biopharmaceutical protein determination [8]. Although some
EPO formulations in the market are formulated with low
molecular mass excipients, some manufacturers use HSA as a
stabilizer, in a quantity of 1–3 mg/mL which is 100 fold more by
weight than the active substance content.
These formulated products require speciﬁc analytical meth-
ods to control the quality of the product. Gunturi et al. have
developed a method for the determination of rHu EPO
aggregates in formulations [9]. Among the possible methods
to eliminate HSA, immunoafﬁnity chromatography (IAC) is
one of the most effective ones [10]. However, there is no
method reported for the determination of EPO in the presence
of HSA without any sample pretreatment. Although HPLC
methodologies have been described previously, they have been
developed either for analysis of puriﬁed r-Hu EPO monomeric
protein [11–13] or for investigation of r-Hu EPO (monomer)
metabolic pathways [14] in the absence of HSA.
Capillary electrophoresis (CE) methods have been devel-
oped to characterize the EPO glycoform pattern and a
capillary zone electrophoresis method has been described in
the EPO monograph of European Pharmacopoeia (EP) as an
identiﬁcation test [15]. In addition to this method, another
CE method has been developed that is capable of analysing
EPO pharmaceutical preparations containing salts and HSA,
in the concentration range of 0.03–1.92 mg/mL of EPO. Luykx
et al. have developed a high-performance anion-exchange chro-
matography (HPAEC) method with intrinsic ﬂuorescence detec-
tion for determination of rHu EPO in pharmaceutical products
[16]. This method appears to be a suitable method for differ-
entiating alpha and beta rHu EPO. Furthermore during the
course of their work when they tried to compare HPAEC
ﬂuorescence detection method with HPAEC UV detection
method, a low signal to noise ratio was obtained, which
attributed to the presence of HPES (N-2- hydroxyethylpipera-
zine-N0-2-ethanesulfonic acid) buffer in the eluent [16].
The objective of the study was to develop methods, using
‘RP-HPLC and UPLC’ techniques to enable quantiﬁcation of
EPO in medicinal formulations containing HSA.
This paper reports rapid and sensitive RP-HPLC and UPLC
methods with UV detection, which are useful for routine quality
control of EPO in different pharmaceutical formulations con-
taining HSA. Both methods were validated by parameters such
as linearity, accuracy, precision and robustness. To the best of
our knowledge, no UPLC method has been reported for the
assay of EPO in the presence of HSA.
2. Experimental
2.1. Materials, reagents and chemicals
HPLC grade acetonitrile was purchased from Merck; tri-
ﬂuoro-acetic acid was purchased from Sigma Aldrich. Ultrapure water was obtained using Milli-Qs UF-Plus (Millipore)
system. HSA with 20% globulin fraction was obtained from
Baxter. EPO internal reference standard (IRS) having 0.8 mg/
mL concentration was used as standard, it was qualiﬁed using
EP reference standard. Formulated EPO was used as samples.
Other chemicals, such as tri-sodium dihydrate, sodium chlor-
ide and citric acid used, were of ‘‘highest purity’’ available.
2.2. Preparation of standard, mobile phase and dilution buffer
Diluted EPO standard was prepared by using 0.8 mg/mL of
EPO IRS and it was used for preparation of different working
standards using dilution buffer or dilution buffer containing
2.5 mg/mL of HSA. Mobile phase ‘A’ consisted of 0.1% (v/v)
TFA in Milli Q water and mobile phase ‘B’ consisted of 0.1%
(v/v) TFA in acetonitrile. Dilution buffer (Citrate buffer)
containing 5.8 mg/mL tri-sodium dihydrate, 5.8 mg/mL
sodium chloride and 0.06 mg/mL citric acid in ‘‘Milli Q water’’
was prepared and used so as to have a matrix similar to EPO
formulation. Dilution buffer with HSA was prepared by
diluting 2.5 mg/mL of HSA in dilution buffer. All dilutions
were made using calibrated digital micro-pipettes.
2.3. Chromatographic condition
An LC system equipped with an injection valve (quaternary),
215 UV detector and chemstation software was used for RP-
HPLC method. A reverse -phase C8 column (4.6 mm ID 250
mm L, porosity 3001 A, particle size 5 mm) with guard column
(reverse-phase C18 column of 4.6 mm ID 35 mm L, porosity
3001 A, particle size 5 mm) was used for separation. To get the
optimum results, mobile phase with a ﬂow rate of 1.5 mL/min
and column temperature at 45 1C were used. The gradient
programme for mobile phase was optimized using a timed
gradient programme T (min)/%mobile phase A: 0/65, 4/65,
12/50, 14/50, 15/40, 16/65, 20/65.
An LC system equipped with an injection valve (binary),
a 210 UV detector and Empower software was used for RP-
UPLC method. Reverse-phase C18 column (2.1 mm ID 50
mm L, porosity 1351A, particle size 1.7 mm) was used for
separation. To get the optimum results, mobile phase ﬂow rate
was kept constant at 0.35 mL/min and column temperature
was set at 60 1C. The gradient programme for mobile phase
was optimized using a timed gradient programme T (min)/%
mobile phase A: 0/85, 0.12/85, 0.33/70, 0.62/64, 2.62/35, 3.19/0,
3.76/85, and 4.05/85.
2.4. Validation of chromatographic methods
The optimized chromatographic methods were validated accord-
ing to the procedures described in ICH guidelines Q2 (R1) [17].
The following validation characteristics were addressed: speciﬁ-
city, linearity and range, accuracy, precision, and robustness.
3. Results and discussion
3.1. RP-HPLC method
3.1.1. Method development
Initially, the gradient HPLC conditions were optimized for
EPO in presence of HSA. The chromatographic separation was
S.S. Rane et al.162achieved by applying chromatographic conditions described in
Section 2.3.
The applied chromatographic conditions permitted a good
separation of HSA and EPO at different concentrations of
EPO each containing 2.5 mg/mL of HSA. No interference of
HSA and other excipients was observed during the analysis as
seen from Fig. 1.
The capacity factor (k0) of ﬁrst peak (HSA) and second
peak (EPO) was 3.24 and 5.24, respectively; while the resolu-
tion factor was 6.88. The asymmetry of the peak was found to
be 1.29 and 5.29 for EPO and HSA, respectively; while the
tailing factor parameter was found to be 1.29 and 1.14 for
EPO and HSA, respectively. For replicate injections of EPO
standard the RSD of the main peak area was found to be
below 0.7%, and there was no variation in the retention time
(less than 0.1 min).
Based on the studied parameters, it was concluded that the
EPO and HSA peaks were well resolved in the developed
method and the tailing factor was within limits.
3.1.2. Method validation
3.1.2.1. Speciﬁcity. To evaluate possible interfering peaks,
three different concentrations of EPO (0.04, 0.1 and 0.4 mg/mL)
with excipients (HSA, tri-sodium dihydrate, sodium chloride
and citric acid) were prepared in mobile phase and in
formulation buffer. No interference was observed.
3.1.2.2. Linearity and range. EPO IRS was used for prepara-
tion of different concentrations of EPO ranging from 0.028 to
0.130 mg/mL, each containing 2.5 mg/mL HSA. Linearity
curves were plotted for 0.04 and 0.1 mg/mL of EPO (Fig. 2).
The correlation coefﬁcient, slope, Y-intercept, regression
equation of the calibration curve were determined and are
shown in Table 1. The percent RSD was found to be less than
2.0% while the percent recovery was found to be in the range
of 97%–103%.
3.1.2.3. Accuracy. Accuracy was studied using two different
sets of three different solutions, containing 0.032, 0.040 and
0.048 mg/mL and 0.08, 0.10 and 0.12 mg/mL of EPO. Each
solution in its formulation buffer and in the mobile phase wasTime (min)
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Figure 1 HPLC chromatograms of internal reference standard of
EPO, HSA in formulation buffer (2.5 mg/mL) and EPO drug
product.spiked with HSA at a concentration of 2.5 mg/mL. The percent
recovery was found to be more than 95% for 0.04 mg/mL of
EPO while the percent recovery was found to be more than
99% for 0.1 mg/mL of EPO in presence of 2.5 mg/mL of HSA.
The percent RSD was found to be less than 2.0%.
3.1.2.4. Precision. Precision was evaluated for inter-day
(Repeatability) and intra-day (Intermediate precision) varia-
tion, and different makes of columns. The repeatability was
assessed with six independent sample preparations for each of
the three different system suitability samples (0.04 mg/mL,
0.1 mg/mL and 0.4 mg/mL of EPO) and single injection was
injected from each preparation. The percent RSD of peak
area, for each EPO IRS was found to be less than 0.9%. Intra-
day precision was determined by a ten fold analysis of
0.04 mg/mL of EPO spiked with 2.5 mg/mL of HSA. The
precision of the method was evaluated by performing ﬁve
different conditions (n¼30) and calculating the relative stan-
dard deviations (RSD). Three replicate injections of system
suitability standards prepared independently were considered
for the study. The percent RSD for the main peak area of EPO
standard within each set and between different sets was found
to be less than 2.0%. The percent recovery of each EPO
standard was found to be between 95.0%–105.0% and the
maximum variation between sets was found to be 5.0%.
3.1.2.5. Robustness. The robustness is a measure of its
capacity to remain unaffected by small, but deliberate varia-
tions in method parameters and provides an indication of its
robustness during normal usage. Robustness was tested using
three variables, age effect of mobile phase and test samples,
column temperature and mobile phase composition.
3.1.2.6. Age effect of mobile phase and test samples held for
seven days. Freshly prepared samples for system suitability
(0.04, 0.1 and 0.4 mg/mL of EPO) and those prepared seven
days ago were analyzed using both freshly prepared and seven
day old mobile phase. There was not much variation in the
results, with percent variation from initial day to 7 day being
about 5% and percent RSD being less than 0.4%. There was
no difference in retention time and percent recovery was found
to be between 90% and 110%. It is thus recommended to use
freshly prepared sample as well as mobile phase for analysis.Figure 2 Linearity curves (HPLC) for 0.04 mg/mL (A) and
0.1 mg/mL (B) EPO.
Table 1 Results of regression equation/correlation coefﬁcient and both methods comparative data.
Statistical parameter HPLC for 0.04 mg/mL HPLC for 0.1 mg/mL UPLC
Linearity and range (Conc. in
mg/mL)
0.028 to 0.052 0.07 to 0.13 0.0025 to 0.15
Regression equation y¼36413.919x150.967 y¼39168.864x357.502 y¼10602431.0891x725.9877
Correlation coefﬁcient (R2) 0.992 0.997 0.999
Total analysis time (min) 20 20 4
Retention time (min)
For HAS 9 1.3
For EPO 13 1.9
Sample size 100 mL 5 mL
Speciﬁcity No interference No interference
Accuracy Recovery more than 95% Recovery more than 97%
Precision RSD less than 2% RSD less than 1.5%
Robustness Method is robust for all tested parameters except age
effect of mobile phase and test samples
Method is robust for all tested parameters.
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ducted using system suitability samples with column tempera-
ture variation of þ2 1C from the set temperature (60 1C). The
percent RSD was found to be less than 0.7%, with no
variation at lower temperature. However, 5% variation was
observed at higher temperature and þ0.1 min difference in
retention time. The percent recovery was found to be within
acceptable limits (95%–105%).
3.1.2.8. Mobile phase composition. Experiments were con-
ducted using system suitability samples with mobile phase
composition variation of þ20% from the set percentage of
TFA (0.1%). The percent variation between unaltered/initial
condition and altered condition for EPO sample (done in
triplicate) was found to vary less than 2.0% and there was no
variation in retention time.
3.2. UPLC method
3.2.1. Method development
The basic chromatographic conditions like stationary phase,
solvents and UV detector, employed in HPLC were taken into
account while developing the new UPLC method. The sta-
tionary phase C18 was chosen in order to have similar polarity
as that used in HPLC method. The injection volume was scaled
down by about 10 fold as used in HPLC. To get the optimum
results, mobile phase ﬂow rate was kept constant at 0.35 mL/
min and column temperature was maintained at 60 1C.
The chromatographic separation was achieved as described
in Section 2.3.
The applied chromatographic conditions permitted a good
separation of HSA and EPO. Different concentrations of EPO
in the range 2.5–150 mg with 2.5 mg/mL of HSA were studied
and no interference of HSA and other excipients was observed
during the analysis. Representative chromatograms are shown
in Fig. 3.
The capacity factor (k0) was 2.45 and 3.9 for the ﬁrst and
second peak respectively, while the resolution factor was 5.35.
The asymmetry of the peak was found to be 5.63 and 1.57 for
HSA and EPO respectively. Tailing factor was found to be
3.68 and 1.33 for HSA and EPO, respectively. The percent
RSD of the main peak area for replicate injections of EPOstandard was found to be below 2.0% while no variation in
the retention time was observed (less than 0.1 min).
3.2.2. Method validation
3.2.2.1. Speciﬁcity. Separation selectivity is the ability of the
method to elicit a response speciﬁc for the analyte in the
presence of other components/substances that are present or
are likely to be present with the analyte.
To address separation selectivity, 0.1 mg/mL of EPO in
mobile phase (as positive control), HSA 2.5 mg/mL in dilution
buffer, HSA 2.5 mg/mL in mobile phase, 0.1 mg/mL of EPO
with 2.5 mg/mL HSA in dilution buffer, mobile phase (Blank),
Milli Q water and dilution buffer were injected into UPLC
column.
HSA in dilution buffer and mobile phase was considered as
the matrix components. Interference by the matrix compo-
nents was evaluated by spiking known amount of EPO IRS in
dilution buffer with HSA. No interference of matrix compo-
nents was observed.
3.2.2.2. Linearity and range. EPO IRS was used for prepara-
tion of different working concentrations ranging from 0.0025
to 0.150 mg/mL, each containing 2.5 mg/mL of HSA. The
peak area was plotted as shown in Fig. 4. Calibration curves
with concentration versus peak area were plotted with blank
subtraction. The correlation coefﬁcient, slopes and Y-inter-
cepts and regression equation were determined and are shown
in Table 1. The correlation coefﬁcient was found to be 0.999.
The percent RSD was found to be less than 2.0% while the
percent recovery was found to be in the range of 97%–103%.
3.2.2.3. Accuracy. Accuracy (% recovery) was studied with
different working concentrations ranging from 0.0025 to
0.150 mg/mL of EPO. Each solution in its formulation buffer
was spiked with HSA at a concentration of 2.5 mg/mL. The
percent recovery was found to be in the range of 96%–103%.
The percent RSD was found to be less than 2.0%.
3.2.2.4. Precision. Precision was evaluated by inter-day
(Repeatability) and intra-day (Intermediate precision) varia-
tion, and different makes of columns. Repeatability (ﬁve
replicates) was assessed independently for each of the three
different concentrations (0.02 mg/mL, 0.04 mg/mL and
0.1 mg/mL). The percent RSD between areas of all ﬁve
A
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Figure 3 UPLC chromatogram of internal reference standard of EPO, HSA in formulation buffer (2.5 mg/mL) and EPO drug product.
Figure 4 Linearity curve (UPLC) for EPO.
S.S. Rane et al.164replicates was less than 1.5% for all dilutions and percent
recovery of all ﬁve replicates was more than 95%.
3.2.2.5. Robustness. To determine the robustness of the
method, experimental condition (TFA concentration) was
purposefully altered and the resolution between EPO and
HSA was examined. The TFA concentration was changed
between 0.08% and 0.12%.
The percent recovery was found to be between 95% and
105%. The percent RSD for the area values obtained with
altered and unaltered conditions of the parameter was found to
be less than 2.5%, thus indicating that the developed method is
robust and TFA concentration is not a critical parameter.
3.3. Comparative study of HPLC and UPLC performance
The performance parameters of both systems are shown in
Table 1. The runtime of UPLC was reduced by 4-fold to that ofHPLC. The retention behaviors of HSA and EPO were similar
in HPLC and UPLC columns. As expected, the UPLC method
showed higher efﬁciency of analysis than HPLC method.4. Conclusion
Both RP-HPLC and RP-UPLC methods were demonstrated
to be validated for quantifying EPO in presence of another
protein (HSA), which is often present in medicinal formula-
tions using HSA as stabilizer. The HPLC and UPLC methods
were validated showing satisfactory data for all the parameters
tested. The reported UPLC method was found to be capable
of giving faster analysis with good resolution, accuracy and
precision than that achieved with conventional HPLC method.
Both the chromatographic methods were found to be reliable.
Since these methods are rapid and simple, they may be
Development and validation of RP-HPLC and RP-UPLC methods 165successfully applied to quality control analysis of EPO
formulation containing HSA.
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